More options updates are on the menu for this morning, with a recap of yesterday’s winners, as well as an update on one of our current running ideas.
From yesterday morning’s premarket report, we have the AMBA Weekly $112-115 Calls and the PLAN 09/17 $65-75 Calls, as well as some new highs in the SLQT 09/17 $7.50-10 Calls which we signaled on Tuesday morning.
AMBA Weekly $112-115 Calls
$112: 7.30-19.96 (+173%)
$113: 7.60-19.00 (+150%)
$115: 3.00-17.60 (+487%)
PLAN 09/17 $65-75 Calls
$65: 3.01-4.66 (+55%)
$70: .92-1.85 (+101%)
$75: .25-.50 (+100%)
SLQT 09/17 $7.50-10 Calls
$7.50: 1.80-3.47 (+93%)
$10: .40-1.25 (+212%)
Fresh Options Ideas:
CHPT Weekly $24-25 Calls
NTNX Weekly $37.50-40 Calls
SIG Weekly $80-90 Calls
CHWY Weekly $83-79 Puts
Medigus Ltd. MDGS – News Alert:
Another fresh PR from MDGS this morning, alluding to a new patent filing pertaining to Polyrizon’s cutting edge infection-resisting hydrogel technology. We’ve been tracking developments in MDGS’ interests, and Polyrizon has been one of the most active.
OMER, Israel, Sept. 02, 2021 (GLOBE NEWSWIRE) — Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in advanced medical solutions, innovative internet technologies and electric vehicle and charging solutions, today announced that Polyrizon Ltd., a privately held company which Medigus owns 35.86% of its share capital, has submitted an additional patent application to the United States Patent and Trademark Office for its innovative technology.
The invention generally pertains to the field of hydrogels that are capable to capture and contain biological assaults intrusion through the upper airways and eye cavities. Furthermore, the invention details a novel modality for a delivery system for drugs through the nasal mucosa that could get more drug into the body, and resides longer in the nasal cavity.
Recent pre-clinical data by Polyrizon, showed that its product candidate has the potential to reduce the risk of an infection with human coronavirus and may also prevent COVID-19 as well as Influenza Virus H1N1 and may potentially also treat additional Cold viruses. (>>Read Full PR HERE)
Metal Arts Co. Inc. MTRT – Recap:
Lastly, we placed MTRT on watch in yesterday morning’s premarket report, and got instant results in the form of an enormous single-session push from this OTC play.
The stock traded up from a low of .5778 on the day, and reach a high of 5.05, for a whopping intraday move of 774% which came in on more than 18X the 30-day average volume.
PSTV, IPHA, SPRT, CHPT, TLSA, GSM, CCAJ, TLSS, TPTW, APTY, RHCO, HBRM